IRIS
LIMONGELLI, VITTORIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.743
AS - Asia 3.592
EU - Europa 2.711
SA - Sud America 402
Continente sconosciuto - Info sul continente non disponibili 197
AF - Africa 98
OC - Oceania 3
Totale 10.746
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.578
SG - Singapore 1.594
RU - Federazione Russa 1.054
VN - Vietnam 709
CN - Cina 635
IT - Italia 634
BR - Brasile 314
DE - Germania 297
HK - Hong Kong 290
FI - Finlandia 171
FR - Francia 112
NL - Olanda 94
CA - Canada 93
GB - Regno Unito 82
IE - Irlanda 69
JP - Giappone 62
IN - India 57
SE - Svezia 55
BD - Bangladesh 53
AR - Argentina 43
UA - Ucraina 38
MX - Messico 31
KR - Corea 30
ZA - Sudafrica 26
CI - Costa d'Avorio 22
ES - Italia 20
IQ - Iraq 19
PH - Filippine 15
PL - Polonia 15
TH - Thailandia 15
TR - Turchia 15
ID - Indonesia 14
PK - Pakistan 14
TW - Taiwan 14
AT - Austria 13
CH - Svizzera 13
EC - Ecuador 10
MA - Marocco 10
MY - Malesia 9
VE - Venezuela 8
JM - Giamaica 7
PY - Paraguay 7
CL - Cile 6
CO - Colombia 6
IL - Israele 6
LT - Lituania 6
NG - Nigeria 6
TT - Trinidad e Tobago 6
AL - Albania 5
BE - Belgio 5
CZ - Repubblica Ceca 5
EG - Egitto 5
HN - Honduras 5
TN - Tunisia 5
AE - Emirati Arabi Uniti 4
CR - Costa Rica 4
JO - Giordania 4
KE - Kenya 4
KZ - Kazakistan 4
OM - Oman 4
PS - Palestinian Territory 4
SA - Arabia Saudita 4
UY - Uruguay 4
AZ - Azerbaigian 3
BY - Bielorussia 3
CG - Congo 3
DZ - Algeria 3
ET - Etiopia 3
MT - Malta 3
NI - Nicaragua 3
NP - Nepal 3
PA - Panama 3
SI - Slovenia 3
SN - Senegal 3
SV - El Salvador 3
AO - Angola 2
AU - Australia 2
BB - Barbados 2
EU - Europa 2
GA - Gabon 2
IR - Iran 2
LB - Libano 2
MQ - Martinica 2
PE - Perù 2
PT - Portogallo 2
RO - Romania 2
A1 - Anonimo 1
BG - Bulgaria 1
BH - Bahrain 1
BN - Brunei Darussalam 1
DK - Danimarca 1
EE - Estonia 1
GE - Georgia 1
GF - Guiana Francese 1
GP - Guadalupe 1
GR - Grecia 1
GT - Guatemala 1
GU - Guam 1
GY - Guiana 1
HT - Haiti 1
Totale 10.535
Salva come PNG Salva come JPEG
Città #
Singapore 710
San Jose 638
Ashburn 375
Hong Kong 278
Moscow 256
Chandler 230
Munich 218
Ho Chi Minh City 204
Beijing 187
Naples 163
Hanoi 144
Santa Clara 135
Los Angeles 110
Helsinki 99
Millbury 98
Council Bluffs 92
Dallas 91
Napoli 83
Lauterbourg 79
The Dalles 79
Hefei 76
Amsterdam 75
New York 75
Nanjing 60
Princeton 60
Buffalo 58
Tokyo 49
Boston 46
Des Moines 45
Ottawa 43
Phoenix 43
Seattle 39
Jacksonville 38
Redondo Beach 31
Wilmington 29
Da Nang 27
Lawrence 26
Haiphong 25
São Paulo 25
Chicago 23
Pune 18
Atlanta 17
Brooklyn 17
Nanchang 17
Stockholm 16
Mexico City 15
Rome 15
Seoul 15
Denver 14
Houston 14
Toronto 14
Turku 14
Tianjin 13
Dong Ket 12
Hebei 12
London 12
Nuremberg 12
Quận Ba 12
Torre Annunziata 12
Warsaw 12
Woodbridge 12
Charlotte 11
Frankfurt am Main 11
Milan 11
Montreal 11
Orem 11
Shenyang 11
Angri 10
Biên Hòa 10
Hải Dương 10
Can Tho 9
Jiaxing 9
Johannesburg 9
Manchester 9
Perugia 9
Poplar 9
San Francisco 9
Ankara 8
Baghdad 8
Boardman 8
Falkenstein 8
Changsha 7
Dhaka 7
Dublin 7
Long Xuyen 7
Phủ Lý 7
Rio de Janeiro 7
Sagrado 7
Salerno 7
Điện Bàn 7
Belo Horizonte 6
Brasília 6
Chennai 6
Curitiba 6
Detroit 6
Formia 6
Jyväskylä 6
Miami 6
Mumbai 6
Pasadena 6
Totale 5.771
Salva come PNG Salva come JPEG
Nome #
Discovery of UDCA derivatives as new modulators of bile acid receptors 307
Potent dual agonists of nuclear and membrane bile acid receptors 281
Calmodulin-Dependent Kinase II Mediates Vascular Smooth Muscle Cell Proliferation and Is Potentiated by Extracellular Signal Regulated Kinase 280
Structural and conformational requisites in DNA quadruplex groove binding: Another piece to the puzzle 199
Discovery of a Novel Class of Dual GPBAR1 Agonists-RORγt Inverse Agonists for the Treatment of IL-17-Mediated Disorders 185
Design, synthesis and pharmacological characterization of novel potent nonsteroidal agonists of the farnesoid X receptor 182
Discovery of a Potent and Orally Active Dual GPBAR1/CysLT1R Modulator for the Treatment of Metabolic Fatty Liver Disease 181
Ligand binding to telomeric G-quadruplex DNA investigated by funnel-metadynamics simulations 176
Novel Isoxazole Derivatives with Potent FXR Agonistic Activity Prevent Acetaminophen-Induced Liver Injury 176
Hyodeoxycholic acid derivatives as liver X receptor α and G-protein-coupled bile acid receptor agonists 164
A New DNA Structural Motif: The G-Triplex 163
Expanding the Library of 1,2,4-Oxadiazole Derivatives: Discovery of New Farnesoid X Receptor (FXR) Antagonists/Pregnane X Receptor (PXR) Agonists 154
Marine and semi-sinthetic hydroxystroids as new scaffolds for pregnane X receptor modulation 154
Structural and conformational requisites in DNA quadruplex groove binding: Another piece to the puzzle 152
Synthesis of new isoxazole derivatives as fxr agonists with improved pharmacokinetic properties 151
Phosphorylation of FAM134C by CK2 controls starvation-induced ER-phagy 150
Structural Basis for Developing Multitarget Compounds Acting on Cysteinyl Leukotriene Receptor 1 and G-Protein-Coupled Bile Acid Receptor 1 149
Discovery of Bile Acid Derivatives as Potent ACE2 Activators by Virtual Screening and Essential Dynamics 149
Computer-Aided Drug Design Unveils the Structural Requisites for Bile Acid Receptors Modulation 143
Identification of cysteinyl-leukotriene-receptor 1 antagonists as ligands for the bile acid receptor GPBAR1 143
Discovery of ((1,2,4-oxadiazol-5-yl)pyrrolidin-3-yl)ureidyl derivatives as selective non-steroidal agonists of the G-protein coupled bile acid receptor-1 141
Design and synthesis of hyodeoxycholic acid derivatives as GPBAR1 receptor modulators useful in the treatment of colon inflammation 139
Breaking the dogma of the metal-coordinating carboxylate group in integrin ligands: introducing hydroxamic acids to the MIDAS to tune potency and selectivity 136
Incisterols, highly degraded marine sterols, are a new chemotype of PXR agonists 136
Minute-timescale free-energy calculations reveal a pseudo-active state in the adenosine A2A receptor activation mechanism 135
Modeling of Cdc25B Dual Specifity Protein Phosphatase Inhibitors: Docking of Ligands and Enzymatic Inhibition Mechanism 133
Ensemble-docking approach on BACE-1: pharmacophore perception and guidelines for drug design 131
Elucidating the Binding Behavior of Highly Potent COX-2 Selective Inhibitors 129
Indolylarylsulfones carrying a heterocyclic tail as very potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors 128
Introduction of Nonacidic Side Chains on 6-Ethylcholane Scaffolds in the Identification of Potent Bile Acid Receptor Agonists with Improved Pharmacokinetic Properties 127
Modification on Ursodeoxycholic Acid (UDCA) Scaffold. Discovery of Bile Acid Derivatives As Selective Agonists of Cell-Surface G-Protein Coupled Bile Acid Receptor 1 (GP-BAR1) 126
Investigation around the Oxadiazole Core in the Discovery of a New Chemotype of Potent and Selective FXR Antagonists 123
The glycan role in the glycopeptide immunogenicity revealed by atomistic simulations and spectroscopic experiments on the multiple sclerosis biomarker CSF114(Glc) 119
Discovery of amine bile acid derivatives as selective agonists of cell-surface G-protein coupled bile acid receptor 1 118
Correction to “Discovery of a Novel Class of Dual GPBAR1 Agonists–RORγt Inverse Agonists for the Treatment of IL-17-Mediated Disorders” 116
Epoxide functionalization on cholane side chains in the identification of G-protein coupled bile acid receptor (GPBAR1) selective agonists 116
GPBAR1 activation by C6-substituted hyodeoxycholane analogues protect against colitis 115
Acetic Acid Aldose Reductase Inhibitors Bearing a Five-Membered Heterocyclic Core with Potent Topical Activity in a Visual Impairment Rat Model. 113
Insight on pregnane-X-receptor modulation. Natural and semisynthetic steroids from Theonella marine sponges 113
Novel N2-substituted pyrazolo[3,4-d]pyrimidine adenosine A3 receptor antagonists: inhibition of A3-mediated human glioblastoma cell proliferation 112
Design, synthesis, and biological evaluation of potent dual agonists of nuclear and membrane bile acid receptors 112
Ligand Binding to Telomeric DNA G-quadruplex through Metadynamics Calculations 110
Dual binding mode of SC-558 in COX-2: A new frontier in COX inhibition 106
Targeting bile acid receptors: discovery of a potent and selective Farnesoid X receptor agonist as a new lead in the pharmacological approach to liver diseases 106
Drug Repurposing on G Protein-Coupled Receptors Using a Computational Profiling Approach 105
Design, Synthesis, and Biological Evaluation of Novel Aminobisphosphonates Possessing an in Vivo Antitumor Activity Through a γδ -T Lymphocytes-Mediated Activation Mechanism. 105
Dual binding mode of SC-558 in COX-2: A new frontier in COX inhibition 105
Design, Synthesis and Biological Evaluation of Carboxy Analogues of Arginine Methyltransferase Inhibitor 1 (AMI-1) 105
The G-triplex DNA 102
Design, synthesis and biologicalevaluation of carboxy analogues of arginine methyltransferase 101
Membrane charge dependent states of the beta -amyloid fragment A beta (16-35) with differently charged micelle aggregates 100
Stop Fitan: Antispasmodic Effect of Natural Extract of Chestnut Wood in Guinea Pig Ileum and Proximal Colon Smooth Muscle 100
Probing the Charge Capability of the MIDAS: Phosphinic- and Phosphonic Acid Containing Compounds as New Potent allb beta 3 Integrin Antagonists 99
gamma-Glutamyl 16-diaminopropane derivative of vasoactive intestinal peptide: a potent anti-oxidative agent for human epidermoid cancer cells 98
Homology Modeling of NR2B Modulatory Domain of NMDA Receptor and Analysis of Ifenprodil Binding. 97
Investigating the mechanism of substrate uptake and release in the glutamate transporter homologue Glt(Ph) through metadynamics simulations. 96
Membrane charge dependent states of the β-amyloid fragment Aβ (16–35) with differently charged micelle aggregates 95
Binding mechanism of the farnesoid X receptor marine antagonist suvanine reveals a strategy to forestall drug modulation on nuclear receptors. Design, synthesis, and biological evaluation of novel ligands 94
Rational Drug Design of New Selective Modulators of GPBAR1 94
Bioinformatics and Biosimulations as Toolbox for Peptides and Peptidomimetics Design: Where Are We? 94
Identification of quinoline-based compounds with dual activity against CysLT1R and GPBAR1 92
Ethyl 8-Fluoro-6-(3-nitrophenyl)-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate as Novel, Highly Potent, and Safe Antianxiety Agent. 88
Potent Arylsulfonamide Inhibitors of Tumor Necrosis Factor-alfa Converting Enzyme Able to Reduce Activated Leukocyte Cell Adhesion Molecule Shedding in Cancer Cell Models 86
Accelerating the Calculation of Protein-Ligand Binding Free Energy and Residence Times Using Dynamically Optimized Collective Variables 85
Structural Insight into the Binding Mode of FXR and GPBAR1 Modulators 85
Structure-based drug design targeting the cell membrane receptor GPBAR1: exploiting the bile acid scaffold towards selective agonism 84
Discovery of a new class of GPBAR1 modulators 83
Disruption of TFGβ-SMAD3 pathway by the nuclear receptor SHP mediates the antifibrotic activities of BAR704, a novel highly selective FXR ligand 81
Transferring chemical and energetic knowledge between molecular systems with machine learning 80
Ligand binding free-energy calculations with funnel metadynamics 78
G-triplex structure and formation propensity 76
Synthesis of new oxadiazole derivatives as potent and selective FXR antagonists 76
Mechanistic insight into ligand binding to G-quadruplex DNA 72
Kinetics of protein-ligand unbinding: Predicting pathways, rates, and rate-limiting steps 71
International Scientific Collaboration Is Needed to Bridge Science to Society: USERN2020 Consensus Statement 69
Conformational Changes in the Epidermal Growth Factor Receptor: Role of the Transmembrane Domain Investigated by Coarse-Grained MetaDynamics Free Energy Calculations 68
The Molecular Mechanism Underlying Ligand Binding to the Membrane-Embedded Site of a G-Protein-Coupled Receptor 68
DDT - Drug Discovery Tool: a fast and intuitive graphics user interface for Docking and Molecular Dynamics analysis 68
To bind or not to bind: diagnosing false positives for 1:1 binding to G-Protein 67
Marine and semi-synthetic hydroxysteroids as new scaffolds for pregnane x receptor modulation. 66
Molecular Modeling for Nanomaterial-Biology Interactions: Opportunities, Challenges, and Perspectives 65
Binding of the Anti-FIV Peptide C8 to Differently Charged Membrane Models: From First Docking to Membrane Tubulation 65
Improving Small-Molecule Force Field Parameters in Ligand Binding Studies 63
Perspectives on High-Throughput Ligand/Protein Docking With Martini MD Simulations 62
Steroidal scaffolds as FXR and GPBAR1 ligands: from chemistry to therapeutical application 62
Unbinding Kinetics of a p38 MAP Kinase Type II Inhibitor from Metadynamics Simulations 61
Promoting transparency and reproducibility in enhanced molecular simulations 60
Tailoring of integrin ligands: probing the charge capability of the metal ion-dependent adhesion site. 58
Ligand binding free energy and kinetics calculation in 2020 58
Funnel-metadynamics and solution NMR to estimate protein-ligand affinities 57
The Free Energy Landscape of GABA Binding to a Pentameric Ligand-Gated Ion Channel and Its Disruption by Mutations 57
Energetics and structural characterization of the large-scale functional motion of adenylate kinase 55
Ligand Binding, Unbinding, and Allosteric Effects: Deciphering Small-Molecule Modulation of HSP90 55
Sampling protein motion and solvent effect during ligand binding. 53
Protein–ligand binding with the coarse-grained Martini model 53
New insight into the central benzodiazepine receptor-ligand interactions: design, synthesis, biological evaluation, and molecular modeling of 3-substituted 6-phenyl-4H-imidazo[1,5-a][1,4]benzodiazepines and related compounds 51
Funnel metadynamics as accurate binding free-energy method 51
Molecular basis of cyclooxygenase enzymes (COXs) selective inhibition 48
Totale 10.746
Salva come PNG Salva come JPEG
Categoria #
all - tutte 36.555
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 36.555
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022435 0 0 0 4 6 15 5 28 68 33 74 202
2022/2023649 91 38 25 42 71 61 11 79 94 73 40 24
2023/2024470 34 62 47 23 23 44 13 57 20 18 91 38
2024/20252.705 136 129 24 29 50 190 383 225 234 220 854 231
2025/20264.994 567 352 506 448 817 136 688 289 503 321 114 253
2026/2027554 107 172 166 109 0 0 0 0 0 0 0 0
Totale 10.746